TATDN2 and Familial prostate cancer: Dysregulation of TATDN2 is associated with a high rate of postoperative recurrence or subsequent metastases in cancers such as uveal melanoma, pancreatic cancer, prostate cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma [86–90].